You are here

psoriasis

Amgen builds Otezla’s psoriasis label as rival BMS looms large

Pharmaforum

Wed, 12/22/21 - 11:19 am

Bristol Myers Squibb

deucravacitinib

Amgen's Otezla notches win in genital psoriasis, snagging possible edge against forthcoming BMS rival

Fierce Pharma

Thu, 12/2/21 - 12:25 pm

Bristol Myers Squibb

Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster

Fierce Biotech

Thu, 10/7/21 - 11:24 am

Bristol Myers Squibb

deucravacitinib

ulcerative colitis

Go or no go? UCB bids to make a mark in psoriasis

EP Vantage

Mon, 10/4/21 - 10:35 am

Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028

Fierce Pharma

Tue, 09/21/21 - 10:54 am

market exclusivity

Coffee talk: Sun brings Ilumya patient stories to light with informal diner meetups

Fierce Pharma

Mon, 08/23/21 - 11:12 am

Next-gen psoriasis drug rivalry between Bristol Myers and Nimbus spills into a legal battle

Endpoints

Tue, 08/17/21 - 10:56 pm

Bristol Myers Squibb

Nimbus Therapeutics

deucravacitinib

Otezla maker Amgen challenges patient groups to help fix long-lasting psoriasis treatment gaps

Fierce Pharma

Fri, 07/23/21 - 11:05 am

Galapagos avoids 'complete whiff' as key anti-inflammatory drug fails to beat placebo in midphase trials

Fierce Biotech

Thu, 07/15/21 - 12:25 pm

clinical trials

rheumatoid arthritis

ulcerative colitis

Crowded psoriasis market cuts Lilly’s mirikizumab ambitions

Pharmaforum

Wed, 04/28/21 - 10:24 am

Lilly scraps IL-23 psoriasis program despite phase 3 success, focuses on IBD race against AbbVie, J&J

Fierce Biotech

Tue, 04/27/21 - 10:50 am

Bristol Myers' next-gen immunology med busts Amgen's Otezla in head-to-head study. Is a showdown coming?

Endpoints

Fri, 04/23/21 - 11:12 am

Bristol Myers Squibb

deucravacitinib

With new PhIII data in hand, Dermavant lines up topical psoriasis contender for a sprint to the finish line

Endpoints

Fri, 04/23/21 - 11:09 am

clinical trials

Amgen Submits Supplemental NDA for Mild-to-Moderate Psoriasis Drug Otezla

BioSpace

Mon, 02/22/21 - 11:49 pm

Dermavant shows deepening effects of tapinarof on psoriasis ahead of FDA filing

Fierce Biotech

Thu, 02/18/21 - 10:57 am

Dermavant Sciences

clinical trials

DiCE gets its 'library' card ready as it speeds development of DNA database-derived molecules with more investor cash

Endpoints

Fri, 01/8/21 - 09:45 am

small molecule drugs

Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis podcast

Fierce Pharma

Sat, 08/29/20 - 11:38 pm

celebrity endorsements

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Pharmaforum

Thu, 08/27/20 - 11:04 am

clinical trials

AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

Fierce Pharma

Tue, 08/25/20 - 11:12 am

Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals

Fierce Pharma

Wed, 07/29/20 - 12:31 pm

Pages